Levels of von Willebrand factor antigen (vWF-Ag) increase during combination antiviral therapy of chronic hepatitis C (CHC). The present study investigates the association between these changes in vWF-Ag levels and response to treatment.
Methods
Changes in levels of vWF-Ag on antiviral combination treatment in 184 patients with CHC genotype 1 or 4 infections were measured prospectively and effect on response was studied.
Results
High on-treatment levels of vWF-Ag were associated with relapse (P<0.01) and low on-treatment levels with sustained virological response (SVR). Receiver operating characteristic curve analysis showed that vWF-Ag levels of <300% at week 12 of therapy have a positive predictive value (PPV) of 78% for SVR. In early virological response (EVR) patients, the PPV of vWF-Ag levels <300% at week 12 was 74%. An even higher PPV of 88% in complete EVRs (undetectable HCV RNA at week 12) was observed for the same cutoff value at week 12.
Conclusions
On-treatment levels of vWF-Ag can be utilized as an additional predictive marker for response to antiviral therapy. This is especially relevant in EVR patients because EVR alone only has a PPV of 58–72% on SVR, which increased to 74%, when factoring in vWF-Ag levels <300% at week 12, and to 88% in complete EVRs; therefore, measurement of vWF-Ag levels at week 12 is helpful. EVR patients that are above the cutoff values for vWF-Ag that make SVR very probable might profit from an extension of therapy to 72 weeks.
References
1.
MannsM.P., McHutchisonJ.G., GordonS.C.Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial.Lancet2001; 358: 958–965.
2.
FriedM.W., ShiffmanM.L., ReddyK.R.Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection.N Engl J Med2002; 347: 975–982.
3.
HoofnagleJ.H., SeeffL.B.Peginterferon and ribavirin for chronic hepatitis C.N Engl J Med2006; 355: 2444–2451.
4.
LeeS.S., FerenciP.Optimizing outcomes in patients with hepatitis C virus genotype 1 or 4.Antivir Ther2008; 13 Suppl 1: 9–16.
5.
FerenciP., FriedM.W., ShiffmanM.L.Predicting sustained virological responses in chronic hepatitis C patients treated with peginterferon alfa-2a (40 KD)/ ribavirin.J Hepatol2005; 43: 425–433.
6.
DavisG.L., WongJ.B., McHutchisonJ.G.Early virologic response to treatment with peginterferon alfa-2b plus ribavirin in patients with chronic hepatitis C.Hepatology2003; 38: 645–652.
7.
StraderD.B., WrightT., ThomasD.L., SeeffL.B.Diagnosis, management, and treatment of hepatitis C.Hepatology2004; 39: 1147–1171.
8.
DaviG., PatronoC.Platelet activation and atherothrombosis.N Engl J Med2007; 357: 2482–2494.
9.
MannucciP.M.Treatment of von Willebrand's Disease.N Engl J Med2004; 351: 683–694.
10.
DaneshJ., WheelerJ.G., HirschfieldG.M.C-reactive protein and other circulating markers of inflammation in the prediction of coronary heart disease.N Engl J Med2004; 350: 1387–1397.
BernardoA., BallC., NolascoL., MoakeJ.F., DongJ-F. Effects of inflammatory cytokines on the release and cleavage of the endothelial cell-derived ultralarge von Willebrand factor multimers under flow.Blood2004; 104: 100–106.
13.
LentingP.J., van SchootenC.J.M., DenisC.V.Clearance mechanisms of von Willebrand factor and factor VIII.J Thromb Haemost2007; 5: 1353–1360.
14.
SieghartW., HomoncikM., JilmaB.Antiviral therapy decreases GpIIb/IIIa activation of platelets in patients with chronic hepatitis C.Thromb Haemost2006; 95: 260–266.
15.
HomoncikM., FerlitschA., FerenciP.Short- and long-term effects of therapy with interferon-alpha and pegylated interferon-alpha/ribavirin on platelet plug formation and von Willebrand factor release in patients with chronic hepatitis C.Aliment Pharmacol Ther2005; 21: 49–55.
16.
SulH.R., ChungS.J., LeeY.J.Higher response rate from peginterferon alpha 2a plus ribavirin in chronic hepatitis C patients with hemophilia.59th Annual Meeting of the American Association for the Study of Liver Diseases. 31 October–4 November 2008, San Francisco, CA, USA. Abstract 1256.
17.
FerenciP., FormannE., LaferlH.Randomized, double-blind, placebo-controlled study of peginterferon alfa-2a (40KD) plus ribavirin with or without amantadine in treatment-naive patients with chronic hepatitis C genotype 1 infection.J Hepatol2006; 44: 275–282.
18.
FerenciP., LaferlH., ScherzerT.M.Peginterferon alfa-2a and ribavirin for 24 weeks in hepatitis C type 1 and 4 patients with rapid virological response.Gastroenterology2008; 135: 451–458.
19.
GoodmanZ.D.Grading and staging systems for inflammation and fibrosis in chronic liver diseases.J Hepatol2007; 47: 598–607.
20.
YuM.L., DaiC.Y., HuangJ.F.Rapid virological response and treatment duration for chronic hepatitis C genotype 1 patients: a randomized trial.Hepatology2008; 47: 1884–1893.
21.
ZeuzemS.Heterogeneous virologic response rates to interferon-based therapy in patients with chronic hepatitis C: who responds less well?Ann Intern Med2004; 140: 370–381.
22.
BergT., SarrazinC., HerrmannE.Prediction of treatment outcome in patients with chronic hepatitis C: significance of baseline parameters and viral dynamics during therapy.Hepatology2003; 37: 600–609.
23.
JensenD.M., MorganT.R., MarcellinP.Early identification of HCV genotype 1 patients responding to 24 weeks peginterferon alpha-2a (40 kd)/ribavirin therapy.Hepatology2006; 43: 954–960.
24.
HondaT., ToyodaH., HayashiK.Ribavirin and use of clotting factors in patients with hemophilia and chronic hepatitis C.JAMA2005; 293: 1190–1192.
25.
ChevaliezS., PawlotskyJ-M. Interferon-based therapy of hepatitis C.Adv Drug Deliv Rev2007; 59: 1222–1241.
